Cargando…

Measuring the effect of drug treatments on primary human CD8+ T cell activation and cytolytic potential

CD8+ T cells are key effector cells in adaptive immune responses against intracellular pathogens and cancer cells. Systemic drug treatments, like chemotherapy, may positively or negatively affect CD8+ T cell function. In this protocol, we describe robust and optimized ex vivo polyclonal activation a...

Descripción completa

Detalles Bibliográficos
Autores principales: Loo Yau, Helen, De Carvalho, Daniel D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8164095/
https://www.ncbi.nlm.nih.gov/pubmed/34095863
http://dx.doi.org/10.1016/j.xpro.2021.100549
_version_ 1783701042992513024
author Loo Yau, Helen
De Carvalho, Daniel D.
author_facet Loo Yau, Helen
De Carvalho, Daniel D.
author_sort Loo Yau, Helen
collection PubMed
description CD8+ T cells are key effector cells in adaptive immune responses against intracellular pathogens and cancer cells. Systemic drug treatments, like chemotherapy, may positively or negatively affect CD8+ T cell function. In this protocol, we describe robust and optimized ex vivo polyclonal activation and cell culture conditions to measure drug treatments' effects on primary human CD8+ T cell activation and cytolytic potential. We provide streamlined methods for measuring effector cytokines and activation markers of CD8+ T cells via flow cytometry. For complete details on the use and execution of this protocol, please refer to Loo Yau et al. (2021).
format Online
Article
Text
id pubmed-8164095
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-81640952021-06-04 Measuring the effect of drug treatments on primary human CD8+ T cell activation and cytolytic potential Loo Yau, Helen De Carvalho, Daniel D. STAR Protoc Protocol CD8+ T cells are key effector cells in adaptive immune responses against intracellular pathogens and cancer cells. Systemic drug treatments, like chemotherapy, may positively or negatively affect CD8+ T cell function. In this protocol, we describe robust and optimized ex vivo polyclonal activation and cell culture conditions to measure drug treatments' effects on primary human CD8+ T cell activation and cytolytic potential. We provide streamlined methods for measuring effector cytokines and activation markers of CD8+ T cells via flow cytometry. For complete details on the use and execution of this protocol, please refer to Loo Yau et al. (2021). Elsevier 2021-05-19 /pmc/articles/PMC8164095/ /pubmed/34095863 http://dx.doi.org/10.1016/j.xpro.2021.100549 Text en © 2021 The Author(s) https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Protocol
Loo Yau, Helen
De Carvalho, Daniel D.
Measuring the effect of drug treatments on primary human CD8+ T cell activation and cytolytic potential
title Measuring the effect of drug treatments on primary human CD8+ T cell activation and cytolytic potential
title_full Measuring the effect of drug treatments on primary human CD8+ T cell activation and cytolytic potential
title_fullStr Measuring the effect of drug treatments on primary human CD8+ T cell activation and cytolytic potential
title_full_unstemmed Measuring the effect of drug treatments on primary human CD8+ T cell activation and cytolytic potential
title_short Measuring the effect of drug treatments on primary human CD8+ T cell activation and cytolytic potential
title_sort measuring the effect of drug treatments on primary human cd8+ t cell activation and cytolytic potential
topic Protocol
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8164095/
https://www.ncbi.nlm.nih.gov/pubmed/34095863
http://dx.doi.org/10.1016/j.xpro.2021.100549
work_keys_str_mv AT looyauhelen measuringtheeffectofdrugtreatmentsonprimaryhumancd8tcellactivationandcytolyticpotential
AT decarvalhodanield measuringtheeffectofdrugtreatmentsonprimaryhumancd8tcellactivationandcytolyticpotential